New NAPSIN1 Antibody Launched by Novus Biologicals

Novus Biologicals is excited to announce the release of a new NAPSIN1 Antibody (NB110-68133) for Napsin research.

Napsin1 (NAPSA) is a peptidase A1 protein that is thought to be involved in pneumocyte surfactant precursor processing. Napsin-1 is most strongly expressed in lung type II pneumocytes and kidney cells, and may be detected at low levels in adult spleen and peripheral blood leukocytes. The Napsin 1 antibody (NB110-68133) may be used in WB and IHC on paraffin embedded human tissue samples.

Novus Biologicals also provides a broad catalog of other cellular markers.  All Novus products are 100% guaranteed to work in the species and applications listed on the datasheet, and the Innovator's Reward Program supports testing in novel species and applications.

About Novus Biologicals (www.novusbio.com)

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science.  Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community.  All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet.  By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

###

Release Date: 
Thursday, April 28, 2011 - 06:00